New data on targeted breast cancer drugs from everyday practice
NCT ID NCT06504719
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these drugs perform outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan and sacituzumab govitecan (antibody-drug conjugates)
What this could lead to
If the results are positive, this could help doctors better understand how these drugs work in everyday practice and guide treatment decisions for advanced breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hellenic Cooperative Oncology Group
Athens, 11524, Greece